Tianjin Pharmaceutical Da Ren Tang Group Limited Receivables

Tianjin Pharmaceutical Da Ren Tang Group Limited (600329.SS) currently reports a receivables of $1.5B as of June 2026. That compares with $1.8B in the prior-year period — down 14.3% year over year. Use the charts on this page to explore Tianjin Pharmaceutical Da Ren Tang Group Limited's receivables history and peer comparisons.

Tianjin Pharmaceutical Da Ren Tang Group Limited's receivables decreased from $1.8B to $1.5B — a 14.3% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Tianjin Pharmaceutical Da Ren Tang Group Limited reported $1.5B in receivables as of June 2026. That compares with $1.8B in the prior-year period — down 14.3% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $1.5B, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Tianjin Pharmaceutical Da Ren Tang Group Limited, and consider following 600329.SS for alerts when major investors trade the stock.